Goethe University
Clinical trials sponsored by Goethe University, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can an immunotherapy drug boost the power of chemoradiation against anal cancer? Results expected Dec 2026 (estimated)
- Could a common supplement supercharge cancer immunotherapy? Results expected Jan 2027 (estimated)
- Zapping the brain to fight alcohol cravings: new study tests promising technique Results expected May 2027 (estimated)
- Robot surgery for bladder cancer: does it reduce bleeding and pain? Results expected May 2027 (estimated)
-
Can an arthritis drug boost rectal cancer therapy?
Disease control CompletedThis trial is testing whether adding anakinra, a drug used for arthritis, to standard chemoradiotherapy is safe for people with rectal cancer. The study will include about 12 patients and will use a dose-escalation design to find the highest tolerable dose of capecitabine when co…
Phase 1 • Sponsor: Goethe University • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Tailored combo therapy boosts leukemia fight in adults
Disease control CompletedThis study tested a personalized, intensive treatment plan for adults aged 18-55 with newly diagnosed acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma. The approach used strong chemotherapy, targeted drugs like nelarabine for T-cell ALL, and risk-based stem cell trans…
Phase 3 • Sponsor: Goethe University • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New combo therapy offers hope for older leukemia patients
Disease control CompletedThis study tested a new treatment approach for adults over 55 with a specific type of leukemia (B-precursor ALL). The goal was to see if using a targeted drug called blinatumomab along with a reduced dose of chemotherapy could help patients achieve remission with fewer side effec…
Phase 2 • Sponsor: Goethe University • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Immunotherapy duo shows promise for Tough-to-Treat kidney cancer
Disease control CompletedThis phase 2 trial tested whether combining two immunotherapy drugs, nivolumab and ipilimumab, works better than standard treatments for people with advanced non-clear cell kidney cancer. About 316 participants received either the drug combo or standard therapy. The main goal was…
Phase 2 • Sponsor: Goethe University • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Do expectant mothers know their Pain-Relief options? survey investigates
Knowledge-focused CompletedThis study surveys pregnant women before their anesthesia consultation to learn what they already know about epidural and spinal pain relief for childbirth, and where that knowledge comes from—such as the internet, friends, or healthcare providers. The goal is to understand the s…
Sponsor: Goethe University • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC